The investigators will also be assessing the following:
1. Whether polymer-based markers can be adequately visualized on daily stereoscopic imaging compared to gold seed markers.
2. Whether polymer-based markers are visible on ultrasound imaging.
3. To determine if the polymer-based marker produces fewer artifacts on treatment planning CT scans than gold markers.
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed prostate adenocarcinoma
diagnosis of low risk or intermediate risk prostate cancer
approved for proton therapy treatment at CDH ProCure Proton Therapy Center
prescribed and consented for the placement of fiducial markers into the prostate as part of the standard treatment procedure
capable of receiving an MRI of the pelvis region for prostate localization
the prostate gland of eligible patients must be capable of imaging from an anterior trans-abdominal ultrasound as determined by the treating investigator
must be fluent in the English language; must be able to provide written study consent
You may not be if
Evidence of a large TURP defect per investigator discretion
previous prostate cancer surgery including prostatectomy, hyperthermia and cryosurgery
previous pelvic radiation for prostate cancer
current grade 2 or above incontinence
history of orthopedic procedures in the area of the treatment, specifically no prior hip replacement or procedure in which metallic or high density material remains which would be within stereoscopic kilovoltage imaging area
prior permanent placement of any metallic or high density material within the prostate
